Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the safety and immunogenicity of FP-01.1 and FP-01.1 reformulated with an adjuvant (FP-01.1-Adjuvant) in relatively healthy subjects 65 to 74 years of age, subjects that are more representative of the target population. Both formulations will be administered alone or concomitantly with the Trivalent Inactivated Influenza Virus (TIV) vaccine.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01701752
Study type Interventional
Source Immune Targeting Systems Ltd
Contact
Status Completed
Phase Phase 1
Start date September 2012
Completion date April 2013

See also
  Status Clinical Trial Phase
Completed NCT03999554 - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines Phase 1
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT02487173 - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B N/A
Enrolling by invitation NCT03207152 - Biomarkers Predicting Infectivity in an Experimental Human Influenza Model Phase 1
Terminated NCT05567783 - A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A Phase 2
Not yet recruiting NCT00987012 - The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients N/A
Not yet recruiting NCT05928507 - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed NCT03651544 - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Phase 1
Completed NCT02623322 - A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults Phase 2
Completed NCT03196661 - Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population Phase 1
Recruiting NCT06160531 - Influenza Viral Challenge Study of CC-42344 in Healthy Participants Phase 2
Recruiting NCT06191393 - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings N/A
Completed NCT06127108 - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel N/A
Completed NCT05163730 - Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel N/A
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT04896853 - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® Phase 1
Not yet recruiting NCT05787444 - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
Completed NCT05354115 - Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel. N/A
Completed NCT02014870 - Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers Phase 1
Completed NCT05897515 - LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia N/A